Experimental drug pacritinib tested for returning prostate cancer – but trial stopped early

NCT ID NCT04635059

Terminated Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited information on how well it works or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pacritinib (an oral drug taken daily)
What this could lead to: If it works, this could point toward a way to delay cancer progression in men whose prostate cancer has returned after initial treatment.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not effectively control the cancer or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.